相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against Acinetobacter spp.
Cristina Lasarte-Monterrubio et al.
ANTIBIOTICS-BASEL (2021)
Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Resistance to ceftazidime-avibactam and underlying mechanisms
Yuhang Wang et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Repositioning rafoxanide to treat Gram-negative bacilli infections
Andrea Miro-Canturri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
Qiwen Yang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii
Carlos Hernan Rodriguez et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2020)
Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations The Price of Progress
Krisztina M. Papp-Wallace et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)
Interplay between β-lactamases and new β-lactamase inhibitors
Karen Bush et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
Melissa D. Barnes et al.
MBIO (2019)
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
Krisztina M. Papp-Wallace
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms
Audrey N. Schuetz et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Humanized Exposures of a β-Lactam-β-Lactamase Inhibitor, Tazobactam, versus Non-β-Lactam-β-Lactamase Inhibitor, Avibactam, with or without Colistin, against Acinetobacter baumannii in Murine Thigh and Lung Infection Models
Marguerite L. Monogue et al.
PHARMACOLOGY (2018)
Intracellular Trafficking and Persistence of Acinetobacter baumannii Requires Transcription Factor EB
Raquel Parra-Millan et al.
MSPHERE (2018)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Thomas F. Durand-Reville et al.
NATURE MICROBIOLOGY (2017)
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
Olga Lomovskaya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model
M. J. Melchers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models
R. Parra Millan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
β-Lactams and β-Lactamase Inhibitors: An Overview
Karen Bush et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
William F. Penwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The -Lactams Strike Back: Ceftazidime-Avibactam
Evan J. Zasowski et al.
PHARMACOTHERAPY (2015)
Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models
Yuta Yokoyama et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Association of the Outer Membrane Protein Omp33 With Fitness and Virulence of Acinetobacter baumannii
Younes Smani et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models
Michael J. McConnell et al.
FEMS MICROBIOLOGY REVIEWS (2013)
Expression of OXA-Type and SFO-1 β-Lactamases Induces Changes in Peptidoglycan Composition and Affects Bacterial Fitness
Ana Fernandez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Platelet-activating Factor Receptor Initiates Contact of Acinetobacter baumannii Expressing Phosphorylcholine with Host Cells
Younes Smani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
In Vitro Activity and In Vivo Efficacy of Clavulanic Acid against Acinetobacter baumannii
Alejandro Beceiro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Does the Activity of the Combination of Imipenem and Colistin In Vitro Exceed the Problem of Resistance in Metallo-β-Lactamase-Producing Klebsiella pneumoniae Isolates?
Maria Souli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Emergence and widespread dissemination of OXA-23,-24/40 and-58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program
Rodrigo E. Mendes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
False extended-spectrum β-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid
A. Beceiro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains
PG Higgins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
A review of the antimicrobial activity of clavulanate
J Finlay et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains
MJ Rodríguez-Hernández et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
分享论文
